Surprisingly, while EGFR inhibition was capable of inducing interferon responses in both EGFR-mutant and wild-type lung cancers, this was NF-κB-independent in EGFR-mutant models but NF-κB-dependent in EGFR wild-type models. The gene discussed is NFKB1; the disease is lung cancer.